Genetic Profile and Patient-reported Outcomes in Chronic Obstructive Pulmonary Disease: A Systematic Review

Overview

Journal PLoS One

Specialties General Medicine
Science

Date 2018 Jun 22

PMID 29927965

Citations 1

Authors

Helder Melro

Jorge Gomes

Gabriela Moura

Alda Marques

Affiliations

Soon will be listed here.

Abstract

Background: Chronic Obstructive Pulmonary Disease (COPD) impacts differently on patients at similar grades, suggesting that factors other than lung function may influence patients' experience of the disease. Recent studies have found associations between genetic variations and patient-reported outcomes (PROs). Identifying these associations might be fundamental to predict the disease progression and develop tailored interventions. This systematic review aimed to identify the genetic variations associated with PROs in COPD.

Methods And Findings: Databases were searched until July 2017 (PROSPERO: CRD42016041639) and additional searches were conducted scanning the reference list of the articles. Two independent reviewers assessed the quality of studies using the Q-Genie checklist. This instrument is composed of 11 questions, each subdivided in 7 options from 1 poor-7 excellent. Thirteen studies reporting 5 PROs in association with genes were reviewed. Studies were rated between "good quality" (n = 8) and "moderate" (n = 5). The most reported PRO was frequency of exacerbations (n = 7/13), which was mainly associated with MBL2 gene variants. Other PRO's were health-related quality of life (HRQOL) (n = 4/13), depressive symptoms (n = 1/13), exacerbation severity (n = 1/13) and breathlessness, cough and sputum (n = 1/13), which were commonly associated with other genetic variants.

Conclusions: Although a limited number of PRO's have been related to genetic variations, findings suggest that there is a significant association between specific gene variants and the number/severity of exacerbations, depressive symptoms and HRQOL. Further research is needed to confirm these findings and assess the genetic influence on other dimensions of patients' lives, since it may enhance our understanding and management of COPD.

Citing Articles

Omega-3 Polyunsaturated Fatty Acids in Managing Comorbid Mood Disorders in Chronic Obstructive Pulmonary Disease (COPD): A Review.

Zailani H, Satyanarayanan S, Liao W, Liao H, Huang S, Galecki P J Clin Med. 2023; 12(7).

PMID: 37048736 PMC: 10095486. DOI: 10.3390/jcm12072653.

References

Mandal J, Malla B, Steffensen R, Costa L, Egli A, Trendelenburg M . Mannose-binding lectin protein and its association to clinical outcomes in COPD: a longitudinal study. Respir Res. 2015; 16:150. PMC: 4750539. DOI: 10.1186/s12931-015-0306-3. View

HO L, Harn H, Chen C, Tsai N . Polymorphism of the beta(2)-adrenoceptor in COPD in Chinese subjects. Chest. 2001; 120(5):1493-9. DOI: 10.1378/chest.120.5.1493. View

Coventry P, Hind D . Comprehensive pulmonary rehabilitation for anxiety and depression in adults with chronic obstructive pulmonary disease: Systematic review and meta-analysis. J Psychosom Res. 2007; 63(5):551-65. DOI: 10.1016/j.jpsychores.2007.08.002. View

Jones P, Miravitlles M, van der Molen T, Kulich K . Beyond FEV₁ in COPD: a review of patient-reported outcomes and their measurement. Int J Chron Obstruct Pulmon Dis. 2012; 7:697-709. PMC: 3476498. DOI: 10.2147/COPD.S32675. View

Zhang J, Zhang J, Fang L, Liu L, Fu W, Dai L . Effect of oral N-acetylcysteine on COPD patients with microsatellite polymorphism in the heme oxygenase-1 gene promoter. Drug Des Devel Ther. 2015; 9:6379-87. PMC: 4676509. DOI: 10.2147/DDDT.S91823. View

Pauwels R, Calverley P, Buist A, Rennard S, Fukuchi Y, Stahl E . COPD exacerbations: the importance of a standard definition. Respir Med. 2004; 98(2):99-107. DOI: 10.1016/j.rmed.2003.09.001. View

Yang I, Seeney S, Wolter J, Anders E, McCormack J, Tunnicliffe A . Mannose-binding lectin gene polymorphism predicts hospital admissions for COPD infections. Genes Immun. 2003; 4(4):269-74. DOI: 10.1038/sj.gene.6363961. View

Pillai S, Kong X, Edwards L, Cho M, Anderson W, Coxson H . Loci identified by genome-wide association studies influence different disease-related phenotypes in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2010; 182(12):1498-505. PMC: 3029936. DOI: 10.1164/rccm.201002-0151OC. View

Zhang J, Zhang J, Liu H, Zhao Z, Fang L, Liu L . Effect of N-acetylcysteine in COPD patients with different microsomal epoxide hydrolase genotypes. Int J Chron Obstruct Pulmon Dis. 2015; 10:917-23. PMC: 4437521. DOI: 10.2147/COPD.S79710. View

10.

Quint J, Donaldson G, Kumari M, Talmud P, Hurst J . SERPINA1 11478G→A variant, serum α1-antitrypsin, exacerbation frequency and FEV1 decline in COPD. Thorax. 2011; 66(5):418-24. DOI: 10.1136/thx.2010.152975. View

11.

Kim S, Lee J, Ha J, Kang H, Rhee C, Kim J . Association between vitamin D receptor polymorphisms and osteoporosis in patients with COPD. Int J Chron Obstruct Pulmon Dis. 2015; 10:1809-17. PMC: 4567171. DOI: 10.2147/COPD.S91576. View

12.

Berndt A, Leme A, Shapiro S . Emerging genetics of COPD. EMBO Mol Med. 2012; 4(11):1144-55. PMC: 3494872. DOI: 10.1002/emmm.201100627. View

13.

Richardson W, Wilson M, Nishikawa J, Hayward R . The well-built clinical question: a key to evidence-based decisions. ACP J Club. 1995; 123(3):A12-3. View

14.

Seemungal T, Donaldson G, Paul E, Bestall J, Jeffries D, Wedzicha J . Effect of exacerbation on quality of life in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 1998; 157(5 Pt 1):1418-22. DOI: 10.1164/ajrccm.157.5.9709032. View

15.

Ekstrom M, Sundh J, Larsson K . Patient reported outcome measures in chronic obstructive pulmonary disease: Which to use?. Expert Rev Respir Med. 2016; 10(3):351-62. DOI: 10.1586/17476348.2016.1146595. View

16.

Pizzo de Castro M, Maes M, Guembarovski R, Ariza C, Reiche E, Vargas H . SLC6A4 STin2 VNTR genetic polymorphism is associated with tobacco use disorder, but not with successful smoking cessation or smoking characteristics: a case control study. BMC Genet. 2014; 15:78. PMC: 4114164. DOI: 10.1186/1471-2156-15-78. View

17.

Patil S, Krishnan J, Lechtzin N, Diette G . In-hospital mortality following acute exacerbations of chronic obstructive pulmonary disease. Arch Intern Med. 2003; 163(10):1180-6. DOI: 10.1001/archinte.163.10.1180. View

18.

Bleecker E, Meyers D, Bailey W, Sims A, Bujac S, Goldman M . ADRB2 polymorphisms and budesonide/formoterol responses in COPD. Chest. 2012; 142(2):320-328. PMC: 3425335. DOI: 10.1378/chest.11-1655. View

19.

Hoidal J . Genetics of COPD: present and future. Eur Respir J. 2002; 18(5):741-3. DOI: 10.1183/09031936.01.00268501. View

20.

Sohani Z, Meyre D, de Souza R, Joseph P, Gandhi M, Dennis B . Assessing the quality of published genetic association studies in meta-analyses: the quality of genetic studies (Q-Genie) tool. BMC Genet. 2015; 16:50. PMC: 4431044. DOI: 10.1186/s12863-015-0211-2. View